Senior Consultant from The University of Hong Kong.
Dr. Kailash Singh is a distinguished researcher and senior consultant specializing in life sciences, with a focus on early drug discovery, oncology, virology, and regulatory science. He has made significant contributions to the development of therapeutic agents targeting hypertension, cancer, and infectious diseases. His work has garnered 442 citations, with an h-index of 12, reflecting sustained impact in his field. Dr. Singh has published 22 peer-reviewed articles, authored a book chapter, and holds a patent for a novel allosteric modulator for hypertension. He is a member of the American Association for Cancer Research (AACR) and actively participates in drug discovery and regulatory science communities. His collaborations with renowned researchers and institutions worldwide underscore his global research network.
Professional Profile
Education:
Dr. Singh’s academic journey is marked by a commitment to excellence in life sciences. He earned his Ph.D. in Biology from the University of Hong Kong, where he conducted pioneering research in molecular biology and pharmacology. In addition to his doctoral studies, he pursued an MBA from Copenhagen Business School, equipping him with a strong foundation in business and management principles. This combination of scientific and business education has enabled Dr. Singh to bridge the gap between research and industry, fostering innovation and facilitating the translation of scientific discoveries into practical applications.
Professional Experience:
Dr. Singh’s professional career spans academia, industry, and consulting, reflecting his versatility and expertise. As a Senior Consultant at Devote Consulting, he provides strategic guidance on regulatory compliance, including MDR and FDA 510(k) submissions in the biotechnology sector. His previous roles include serving as a Strategy Analyst at LEO Pharma, where he led market analyses and competitive reports for major projects. At ImmunoDiagnostics Limited, he managed the establishment of a diagnostic lab and developed targeted go-to-market strategies. As a founding partner of PhrmaSec Limited, Dr. Singh played a vital role in securing funding for research initiatives. His academic tenure as a Postdoctoral Researcher at the University of Hong Kong involved leading interdisciplinary projects and fostering collaborations within the scientific community.
Research Interests:
Dr. Singh’s research interests are diverse and encompass several critical areas in life sciences. He focuses on early drug discovery and pre-clinical research, particularly in developing novel therapeutic agents for hypertension, cancer, and infectious diseases. His work on allosteric modulators for G protein-coupled receptors (GPCRs) has significant implications for drug development. Additionally, Dr. Singh investigates biomarkers for neurodegenerative diseases, aiming to enhance diagnostic and therapeutic strategies. His expertise extends to Software as a Medical Device (SaMD) and in vitro diagnostic (IVD) regulatory compliance, ensuring that innovative medical technologies meet stringent regulatory standards.
Research Skills:
Dr. Singh possesses a comprehensive skill set that spans various aspects of life sciences research. He is proficient in molecular biology techniques, including cell culture, biochemical assays, and molecular dynamics simulations. His expertise in bioinformatics enables him to analyze complex biological data, facilitating the identification of potential drug targets. Dr. Singh has experience in developing standard operating procedures (SOPs) for the production of in vitro diagnostic products, optimizing quality and reproducibility. His project management skills are demonstrated through the successful completion of multiple research projects and the establishment of diagnostic services. Additionally, he has contributed to securing research funding and has a strong background in scientific writing, with numerous publications in high-impact journals.
Conclusion:
Dr. Kailash Singh’s extensive academic background, diverse professional experience, and significant research contributions underscore his standing as a leading figure in life sciences. His interdisciplinary expertise bridges the gap between scientific research and industry application, fostering innovation and advancing healthcare solutions. Dr. Singh’s commitment to excellence is evident in his numerous publications, patents, and active participation in professional communities. His dedication to mentoring emerging scientists and his collaborative approach to research further enhance his impact in the scientific community. Dr. Singh’s work continues to inspire and influence the fields of drug discovery, regulatory science, and translational research.
Publication Top Notes
- “A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase”
- Authors: Shuofeng Yuan, Hin Chu, Kailash Singh, Hanjun Zhao, Ke Zhang, Richard Y.T. Kao, Billy K.C. Chow, Jie Zhou, Bo-Jian Zheng
- Year: 2016
- Citations: 51
- Source: Scientific Reports, Volume 6, Article 22880
- DOI: 10.1038/srep22880
- Summary: This study identifies a small-molecule compound, ANA-0, that inhibits the replication of multiple subtypes of influenza A virus by suppressing the PA endonuclease activity of the viral polymerase.
- “PB2 substitutions V598T/I increase the virulence of H7N9 influenza A virus in mammals”
- Authors: Meng Hu, Shuofeng Yuan, Ke Zhang, Kailash Singh, Qiang Ma, Jie Zhou, Hin Chu, Bo-Jian Zheng
- Year: 2017
- Citations: 50
- Source: Virology, Volume 501, Pages 92-101
- DOI: 10.1016/j.virol.2016.11.008
- Summary: The research demonstrates that PB2 substitutions V598T/I enhance the replication and virulence of H7N9 influenza A virus in mammalian models.
- “Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase”
- Authors: Shuofeng Yuan, Hin Chu, Hanjun Zhao, Ke Zhang, Kailash Singh, Billy K.C. Chow, Richard Y.T. Kao, Jie Zhou, Bo-Jian Zheng
- Year: 2016
- Citations: 49
- Source: Antiviral Research, Volume 125, Pages 34-42
- DOI: 10.1016/j.antiviral.2015.11.005
- Summary: This paper reports the identification of a small-molecule inhibitor that disrupts the interaction between subunits of the influenza virus polymerase, thereby inhibiting viral replication.
- “Cross-protection of influenza A virus infection by a DNA aptamer targeting the PA endonuclease domain”
- Authors: Shuofeng Yuan, N. Zhang, Kailash Singh, H. Shuai, Hin Chu, Jie Zhou, Billy K.C. Chow, Bo-Jian Zheng
- Year: 2015
- Citations: 47
- Source: Antimicrobial Agents and Chemotherapy, Volume 59, Issue 7, Pages 4082-4093
- DOI: 10.1128/AAC.04847-14
- Summary: The study investigates the use of a DNA aptamer targeting the PA endonuclease domain of influenza A virus, demonstrating its potential for cross-protection against various influenza strains.
- “A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication”
- Authors: Shuofeng Yuan, Hin Chu, Ke Zhang, Jie Ye, Kailash Singh, Richard Y.T. Kao, Billy K.C. Chow, Jie Zhou, Bo-Jian Zheng
- Year: 2016
- Citations: 36
- Source: Journal of Antimicrobial Chemotherapy, Volume 71, Issue 9, Pages 2489-2497
- DOI: 10.1093/jac/dkw194
- Summary: This research identifies a small-molecule compound that disrupts the PB2 cap-binding activity of the influenza A virus, effectively inhibiting viral replication.
- “Amino acid substitutions V63I or A37S/I61T/V63I/V100A in the PA N-terminal domain increase the virulence of H7N7 influenza A virus”
- Authors: Meng Hu, Hin Chu, Ke Zhang, Kailash Singh, C. Li, Shuofeng Yuan, Billy K.C. Chow, W. Song, Bo-Jian Zheng
- Year: 2016
- Citations: 31
- Source: Scientific Reports, Volume 6, Article 37800
- DOI: 10.1038/srep37800
- Summary: The study explores how specific amino acid substitutions in the PA N-terminal domain can enhance the virulence of H7N7 influenza A virus in mammalian hosts.
- “Pharmacological actions of glucagon-like peptide-1, gastric inhibitory polypeptide, and glucagon”
- Authors: R. Sekar, Kailash Singh, A.W.R. Arokiaraj, Billy K.C. Chow
- Year: 2016
- Citations: 29